CN101703754B

CN101703754B - Nasal preparation for treating white-plus disease and preparation method thereof

Info

Publication number: CN101703754B
Application number: CN2009102112636A
Authority: CN
Inventors: 陈丽娟; 张樱山; 张国霞; 李波
Original assignee: Gansu Qizheng Tibetan Medicine Co Ltd
Current assignee: Gansu Qizheng Tibetan Medicine Co Ltd
Priority date: 2009-11-05
Filing date: 2009-11-05
Publication date: 2011-11-23
Anticipated expiration: 2029-11-05
Also published as: CN101703754A

Abstract

The invention discloses a nasal preparation for treating white-plus disease and a preparation method thereof. The nasal preparation is prepared by taking a formula of the conventional Tibetan medicament white-plus unguent as a basic formula and modifying the formulation. In the invention, an adopted preparation method of extracting some medicinal materials and making other medicinal materials into superfine powder effectively retains the active ingredients of the medicinal materials, greatly improves the raw medicament component content and improves bioavailability so that the curative effect of the preparation is better. The auxiliary material selected and applied in the invention has good moldability so that a product has good permeability, better absorption and quicker response and the advantages of convenient administration, long duration, low allergy rate, convenient usage and carrying, no pollution to clothes and the like; and in the invention, a nasal mucosa administration system is adopted, so that the preparation has quick absorption, quick response, no stimulation nor unpleasant odor.

Description

A kind of nasal formulations for the treatment of aortic arch syndrome and preparation method thereof

Invention field

The present invention relates to a kind of nasal formulations and preparation method thereof, particularly a kind of nasal formulations for the treatment of aortic arch syndrome and preparation method thereof.

Technical background

The lung-pulse ointment is that the doctor among the people of Tibetan is carried according to " Tibetan medicine doctor certainly addendum releases difficulty ", the Four-Volume Medical Code two secretaries, in conjunction with the classical Tibetan medicine and pharmacology proved recipe that practical experience is formed, the lung-pulse ointment is former to be recorded in first 310 pages of " health drug standard promulgated by the ministries or commissions of the Central Government " 95 years version Tibetan medicines.The prescription of the lung-pulse ointment is:

Rhizoma Curcumae Longae 150g, Semen Myristicae 50g, Radix Et Rhizoma Nardostachyos 80g, Actinolitum 50g, Radix Glycyrrhizae 70g, artificial Moschus or Moschus 0.7g, Rhizoma Kaempferiae 100g, Fructus cari carvi 130g, Rhizoma Acori Calami 70g, Pericarpium Zanthoxyli 50g, trona 75g.

Method for making: above ten simply, and except that artificial Moschus or other porphyrize powder of Moschus, all the other are ground into fine powder altogether, sieve, and add artificial Moschus or Moschus fine powder facing-up, with butter and Adeps Sus domestica furnishing ointment, promptly.

Function with cure mainly: relaxing muscles and tendons and activating QI and blood in the collateral.Be used for aortic arch syndrome, paralysis, hemiplegia, the muscle tendon is tetanic, meridians that wound causes and muscle tendon break wound, brothers' contraction urgency, limping etc.

According to Tibetan medicine's theory, disorders of meridian is divided into the lung-pulse and Hei Mai, wherein the lung-pulse is the venation that human body at first bears at embryo stage, it also is the venation that fetal development obtains nutrition, these venations of birth back play again and absorb diet elite, conveying waste matter, to guarantee the normal circulation of three factors, seven materials,, can cause the generation of various diseases if the function of these venations gets muddled.The main pathogenic factor of aortic arch syndrome has following three aspects: aggravating activities, damage body venation; Pestilent toxicity pathogenic heat etc. is fallen in the arteries and veins; Mechanical damages such as weapons club cause rheumatism; In disorder and go into sering.The Tibetan medicine is the vital energy regualting and blood circulation-promoting collateral dredging to the regulation principle of aortic arch syndrome.Tibetan people is according to the Four-Volume Medical Code, " brilliant pearl book on Chinese herbal medicine " record, in conjunction with long-term practical experience, with Rhizoma Curcumae Longae, Semen Myristicae, Radix Et Rhizoma Nardostachyos, Actinolitum, Radix Glycyrrhizae, Rhizoma Kaempferiae, Moschus, Fructus cari carvi, Pericarpium Zanthoxyli, trona is the Tibetan medicine the lung-pulse ointment of raw material production, be subjected to the trust of extensive patients with significant mass effect, but traditional Tibetan medicine the lung-pulse ointment preparation technology is modulated into ointment after all crude drug fine powders are mixed, its technology is numerous and diverse, and batch production cycle is long, the production technology instability; Raw material and adjuvant source are unstable, are unfavorable for suitability for industrialized production; Part drug osmotic ability, bioavailability is low, can not guarantee curative effect fully, should not bring into play the curative effect of medicine; Product should not be deposited in addition, carries inconvenience; Because each side has greatly influenced the curative effect and the popularization of product.

Summary of the invention

It is the nasal formulations that basic square tube is crossed the treatment aortic arch syndrome that dosage changing form prepares that the object of the invention is to disclose a kind of prescription with traditional Tibetan medicine the lung-pulse ointment, and the object of the invention also is to disclose the preparation method of this nasal formulations.

The present invention seeks to be achieved through the following technical solutions.

The crude drug of nasal formulations of the present invention is formed and consumption is:

Rhizoma Curcumae Longae 30-40 weight portion, Semen Myristicae 10-15 weight portion, Radix Et Rhizoma Nardostachyos 15-25 weight portion, Actinolitum 10-15 weight portion, Radix Glycyrrhizae 15-20 weight portion, artificial Moschus or Moschus 0.15-0.2 weight portion, Rhizoma Zingiberis 20-28 weight portion, Fructus cari carvi 28-35 weight portion, Rhizoma Acori Calami 15-20 weight portion, Pericarpium Zanthoxyli 10-15 weight portion, trona 15-20 weight portion.

The crude drug of nasal formulations of the present invention is formed and consumption is preferably:

Rhizoma Curcumae Longae 36.3 weight portions, Semen Myristicae 12.1 weight portions, Radix Et Rhizoma Nardostachyos 19.4 weight portions, Actinolitum 12.1 weight portions, Radix Glycyrrhizae 17.0 weight portions, artificial Moschus or Moschus 0.17 weight portion, Rhizoma Zingiberis 24.2 weight portions, Fructus cari carvi 31.5 weight portions, Rhizoma Acori Calami 17.0 weight portions, Pericarpium Zanthoxyli 12.1 weight portions, trona 18.2 weight portions.

The adjuvant of nasal formulations of the present invention is formed and consumption is:

Cosolvent: one or more in glycerol 5-250 weight portion, propylene glycol 5-1500 weight portion and the ethanol 5-250 weight portion;

Buffer agent: one or more in Borax sodium carbonate buffer 75-600 parts by volume, phosphate buffer 60-650 parts by volume, borate buffer solution 100-850 parts by volume and the acetate buffer 150-3200 parts by volume;

PH regulator: one or more in sodium hydroxide 0-80 parts by volume, sodium bicarbonate 0-150 parts by volume, sodium hydrogen phosphate 0-200 parts by volume and the sodium citrate 0-100 parts by volume;

Stabilizing agent: one or more in sodium pyrosulfite 0-100 weight portion, sodium sulfite 0-200 weight portion, sodium sulfite 0-175 weight portion, sodium thiosulfate 0-450 weight portion, ascorbic acid 0-150 weight portion, disodiumedetate (EDTA-2Na) 0-150 weight portion, ethylenediaminetetraacetic acid 0-450 weight portion, citric acid 0-50 weight portion and the tartaric acid 0-50 weight portion;

Isoosmotic adjusting agent: one or more in sodium chloride 0-220 weight portion, glucose 0-200 weight portion, mannitol 0-650 weight portion, sorbitol 0-700 weight portion and the xylitol 0-200 weight portion;

Antibacterial: one or more in parabens 0-15 weight portion, phenethanol 0-10 weight portion, sodium benzoate 0-20 weight portion and the sorbic acid 0-50 weight portion.

The adjuvant of nasal formulations of the present invention is formed and consumption is preferably:

Cosolvent: one or more in glycerol 55-200 weight portion, propylene glycol 100-1400 weight portion and the ethanol 55-200 weight portion;

Buffer agent: one or more in Borax sodium carbonate buffer 150-500 parts by volume, phosphate buffer 1 00-600 parts by volume, borate buffer solution 200-750 parts by volume and the acetate buffer 550-3000 parts by volume;

PH regulator: one or more in sodium hydroxide 20-60 parts by volume, sodium bicarbonate 20-130 parts by volume, sodium hydrogen phosphate 50-150 parts by volume and the sodium citrate 20-80 parts by volume;

Stabilizing agent: one or more in sodium pyrosulfite 20-80 weight portion, sodium sulfite 50-150 weight portion, sodium sulfite 25-150 weight portion, sodium thiosulfate 50-400 weight portion, ascorbic acid 20-130 weight portion, disodiumedetate (EDTA-2Na) 20-130 weight portion, ethylenediaminetetraacetic acid 50-400 weight portion, citric acid 10-40 weight portion and the tartaric acid 10-40 weight portion;

Isoosmotic adjusting agent: one or more in sodium chloride 20-200 weight portion, glucose 50-150 weight portion, mannitol 50-600 weight portion, sorbitol 100-600 weight portion and the xylitol 50-150 weight portion;

Antibacterial: one or more in parabens 2-13 weight portion, phenethanol 2-8 weight portion, sodium benzoate 5-15 weight portion and the sorbic acid 10-40 weight portion.

Cosolvent: one or more in glycerol 122 weight portions, propylene glycol 750 weight portions and ethanol 123 weight portions;

Buffer agent: one or more in Borax sodium carbonate buffer 340 parts by volume, phosphate buffer 305 parts by volume, borate buffer solution 475 parts by volume and acetate buffer 1675 parts by volume;

PH regulator: one or more in sodium hydroxide 40 parts by volume, sodium bicarbonate 75 parts by volume, sodium hydrogen phosphate 100 parts by volume and sodium citrate 50 parts by volume;

Stabilizing agent: one or more in sodium pyrosulfite 50 weight portions, sodium sulfite 100 weight portions, sodium sulfite 90 weight portions, sodium thiosulfate 225 weight portions, ascorbic acid 75 weight portions, disodiumedetate (EDTA-2Na) 75 weight portions, ethylenediaminetetraacetic acid 225 weight portions, citric acid 25 weight portions and tartaric acid 25 weight portions;

Isoosmotic adjusting agent: one or more in sodium chloride 110 weight portions, glucose 100 weight portions, mannitol 325 weight portions, sorbitol 350 weight portions and xylitol 100 weight portions;

Antibacterial: one or more in parabens 7 weight portions, phenethanol 5 weight portions, sodium benzoate 10 weight portions and sorbic acid 25 weight portions.

Cosolvent: one or more in glycerol 10 weight portions, propylene glycol 1400 weight portions and ethanol 10 weight portions;

Buffer agent: one or more in Borax sodium carbonate buffer 590 parts by volume, phosphate buffer 65 parts by volume, borate buffer solution 840 parts by volume and acetate buffer 160 parts by volume;

PH regulator: one or more in sodium hydroxide 5 parts by volume, sodium bicarbonate 145 parts by volume, sodium hydrogen phosphate 5 parts by volume and sodium citrate 95 parts by volume;

Stabilizing agent: one or more in sodium pyrosulfite 95 weight portions, sodium sulfite 5 weight portions, sodium sulfite 170 weight portions, sodium thiosulfate 5 weight portions, ascorbic acid 145 weight portions, disodiumedetate (EDTA-2Na) 5 weight portions, ethylenediaminetetraacetic acid 440 weight portions, citric acid 5 weight portions and tartaric acid 45 weight portions;

Isoosmotic adjusting agent: one or more in sodium chloride 5 weight portions, glucose 195 weight portions, mannitol 5 weight portions, sorbitol 690 weight portions and xylitol 5 weight portions;

Antibacterial: one or more in parabens 10 weight portions, phenethanol 1 weight portion, sodium benzoate 15 weight portions and sorbic acid 5 weight portions.

Cosolvent: one or more in glycerol 245 weight portions, propylene glycol 10 weight portions and ethanol 245 weight portions;

Buffer agent: one or more in Borax sodium carbonate buffer 80 parts by volume, phosphate buffer 640 parts by volume, borate buffer solution 105 parts by volume and acetate buffer 3100 parts by volume;

PH regulator: one or more in sodium hydroxide 75 parts by volume, sodium bicarbonate 5 parts by volume, sodium hydrogen phosphate 195 parts by volume and sodium citrate 5 parts by volume;

Stabilizing agent: one or more in sodium pyrosulfite 5 weight portions, sodium sulfite 195 weight portions, sodium sulfite 10 weight portions, sodium thiosulfate 440 weight portions, ascorbic acid 10 weight portions, disodiumedetate (EDTA-2Na) 145 weight portions, ethylenediaminetetraacetic acid 10 weight portions, citric acid 45 weight portions and tartaric acid 5 weight portions;

Isoosmotic adjusting agent: one or more in sodium chloride 215 weight portions, glucose 10 weight portions, mannitol 640 weight portions, sorbitol 10 weight portions and xylitol 195 weight portions;

Antibacterial: one or more in parabens 1 weight portion, phenethanol 5 weight portions, sodium benzoate 1 weight portion and sorbic acid 45 weight portions.

Borax sodium carbonate buffer 580 parts by volume, glycerol 30 weight portions, sodium chloride 30 weight portions, sodium sulfite 10 weight portions, sodium bicarbonate solution 15 parts by volume, sodium benzoate 3.0 weight portions;

Or phosphate buffer 550 parts by volume, propylene glycol 12 weight portions, glucose 17.5 weight portions, sodium pyrosulfite 10 weight portions, disodium phosphate soln 10 parts by volume, methyl hydroxybenzoate 2.5 weight portions;

Or borate buffer solution 600 parts by volume, ethanol 15 weight portions, mannitol 20 weight portions, sodium sulfite 18 weight portions, sodium hydroxide solution 20 parts by volume, sorbic acid 2.5 weight portions;

Or acetate buffer 410 parts by volume, propylene glycol 40 weight portions, sorbitol 30 weight portions, disodiumedetate 18 weight portions, liquor sodii citratis 15 parts by volume, phenethanol 1.5 weight portions;

Or phosphate buffer 425 parts by volume, glycerol 45 weight portions, xylitol 28 weight portions, sodium thiosulfate 25 weight portions, sodium bicarbonate solution 35 parts by volume, ethyl hydroxybenzoate 5.0 weight portions;

Or acetate buffer 530 parts by volume, ethanol 22 weight portions, sodium chloride 14 weight portions, citric acid 7.5 weight portions, sodium hydroxide solution 10 parts by volume, propylparaben 2.0 weight portions;

Or phosphate buffer 600 parts by volume, sodium chloride 150 weight portions, ascorbic acid 60 weight portions, sodium bicarbonate solution 50 parts by volume, sodium benzoate 9.0 weight portions;

Or Borax sodium carbonate buffer 515 parts by volume, glucose 12 weight portions, tartaric acid 7 weight portions, sodium hydroxide solution 20 parts by volume, butoben 1.5 weight portions;

Or acetate buffer 2850 parts by volume, mannitol 550 weight portions, ethylenediaminetetraacetic acid 350 weight portions, disodium phosphate soln 150 parts by volume, sorbic acid 20 weight portions;

Or borate buffer solution 620 parts by volume, xylitol 150 weight portions, sodium sulfite 85 weight portions, liquor sodii citratis 50 parts by volume, phenethanol 5.0 weight portions;

Or phosphate buffer 580 parts by volume, sodium chloride 180 weight portions, sodium sulfite 115 weight portions, sodium bicarbonate solution 60 parts by volume, methyl hydroxybenzoate 4.5 weight portions;

Or Borax sodium carbonate buffer 650 parts by volume, mannitol 150 weight portions, disodiumedetate 100 weight portions, disodium phosphate soln 50 parts by volume, propylparaben 5.0 weight portions;

Or phosphate buffer 450 parts by volume, glycerol 160 weight portions, glucose 120 weight portions, sodium pyrosulfite 65 weight portions, sodium hydroxide solution 50 parts by volume, methyl hydroxybenzoate 2.5 weight portions;

Or acetate buffer 1750 parts by volume, propylene glycol 1050 weight portions, sorbitol 580 weight portions, sodium thiosulfate 350 weight portions, sodium bicarbonate solution 100 parts by volume, sodium benzoate 8.5 weight portions;

Or phosphate buffer 400 parts by volume, ethanol 200 weight portions, glucose 150 weight portions, ethylenediaminetetraacetic acid 85 weight portions, liquor sodii citratis 45 parts by volume, propylparaben 7.5 weight portions;

Or Borax sodium carbonate buffer 540 parts by volume, glycerol 180 weight portions, sodium chloride 90 weight portions, ascorbic acid 75 weight portions, disodium phosphate soln 70 parts by volume, phenethanol 4.5 weight portions;

Or acetate buffer 420 parts by volume, propylene glycol 195 weight portions, xylitol 160 weight portions, sodium sulfite 120 weight portions, sodium bicarbonate solution 80 parts by volume, methyl hydroxybenzoate 2.5 weight portions;

Or phosphate buffer 355 parts by volume, glycerol 85 weight portions, glucose 18 weight portions, tartaric acid 12 weight portions, sodium hydroxide 30 parts by volume, sodium benzoate 2.5 weight portions;

Or Borax sodium carbonate buffer 415 parts by volume, glucose 25 weight portions, tartaric acid 18 weight portions, sodium hydroxide solution 20 parts by volume, butoben 1.5 weight portions;

Or phosphate buffer 400 parts by volume, ethanol 200 weight portions, glucose 150 weight portions, ethylenediaminetetraacetic acid 85 weight portions, liquor sodii citratis 45 parts by volume, propylparaben 4.5 weight portions;

Or phosphate buffer 600 parts by volume, glycerol 85 weight portions, glucose 30 weight portions, tartaric acid 28 weight portions, sodium hydroxide 30 parts by volume, sodium benzoate 2.5 weight portions.

The preparation method of nasal formulations of the present invention comprises a kind of in following A and the B method:

The A method:

1. artificial Moschus or Moschus are ground to form fine powder;

2. Rhizoma Curcumae Longae, Semen Myristicae, dry and soft, Actinolitum, Radix Glycyrrhizae, Rhizoma Zingiberis, Fructus cari carvi, Rhizoma Acori Calami, Pericarpium Zanthoxyli and trona are picked totally, be ground into the medicated powder that particle diameter is 0.1-150 μ m;

3. the artificial Moschus or the Moschus fine powder mix homogeneously that 1. obtain of medicated powder that 2. above-mentioned steps is obtained and step, add buffer agent, cosolvent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.0-7.0, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention;

The B method:

1. artificial Moschus or Moschus are ground to form fine powder;

2. with Rhizoma Curcumae Longae, Semen Myristicae, dry and soft, Actinolitum, Radix Glycyrrhizae, Rhizoma Zingiberis, Fructus cari carvi, Rhizoma Acori Calami, Pericarpium Zanthoxyli and trona remove impurity, clean system is mixed;

3. take by weighing the 10%-100% of the hybrid medicine total amount that 2. above-mentioned steps obtain, boil 1-4 time with 5-20 times of decocting of medicine gross weight, the each decoction 0.5-3 hour, collection, merge extractive liquid, and volatile oil, it is the concentrated solution of 1.0-1.5 that filtration and concentrated extracting solution become relative density, and volatile oil joined in the concentrated solution, concentrated solution a;

Or take by weighing the 10%-100% of above-mentioned hybrid medicine total amount, and with medicine gross weight 5-20 30-90% ethanol extraction doubly 1-4 time, extracted 0.5-24 hour at every turn, collect extracting solution, filtration, being condensed into relative density is the concentrated solution a of 1.0-1.5;

4. will remain hybrid medicine and be ground into the medicated powder that particle diameter is 0.1-150 μ m;

5. the medicated powder that 4. artificial Moschus that 1. concentrated solution a that 3. above-mentioned steps is obtained and step obtain or Moschus fine powder, step obtain, mix homogeneously, add buffer agent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.0-7.0, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention;

Or after the concentrated solution a spray drying that 3. above-mentioned steps is obtained the medicated powder that 4. obtains of the artificial Moschus that 1. obtains of extract dry powder and step or Moschus fine powder, step, mix homogeneously, add buffer agent, cosolvent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.0-7.0, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

The preparation method of nasal formulations of the present invention preferably includes a kind of in following A and the B method:

The A method:

1. artificial Moschus or Moschus are ground to form fine powder;

2. Rhizoma Curcumae Longae, Semen Myristicae, dry and soft, Actinolitum, Radix Glycyrrhizae, Rhizoma Zingiberis, Fructus cari carvi, Rhizoma Acori Calami, Pericarpium Zanthoxyli and trona are picked totally, be ground into the superfine powder that particle diameter is 0.1-1 μ m;

3. the artificial Moschus or the Moschus fine powder mix homogeneously that 1. obtain of superfine powder that 2. above-mentioned steps is obtained and step, add buffer agent, cosolvent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention;

The B method:

1. artificial Moschus or Moschus are ground to form fine powder;

3. take by weighing 10% of hybrid medicine total amount that 2. above-mentioned steps obtain, boil 4 times with 5 times of decoctings of medicine gross weight, the each decoction 3 hours, collection, merge extractive liquid, and volatile oil, it is the concentrated solution of 1.25-1.35 that filtration and concentrated extracting solution become relative density, and volatile oil joined in the concentrated solution, concentrated solution a;

Or take by weighing 10% of above-mentioned hybrid medicine total amount, and 30% ethanol extraction that usefulness medicine gross weight is 5 times 4 times extracted 3 hours at every turn, collected extracting solution, filtered, and being condensed into relative density is the concentrated solution a of 1.25-1.35;

4. will remain hybrid medicine and be ground into the superfine powder that particle diameter is 0.1-1 μ m;

5. the superfine powder that 4. artificial Moschus that 1. concentrated solution a that 3. above-mentioned steps is obtained and step obtain or Moschus fine powder, step obtain, mix homogeneously, add buffer agent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention;

Or after the concentrated solution a spray drying that 3. above-mentioned steps is obtained the superfine powder that 4. obtains of the artificial Moschus that 1. obtains of extract dry powder and step or Moschus fine powder, step, mix homogeneously, add buffer agent, cosolvent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

The A method:

1. artificial Moschus or Moschus are ground to form fine powder;

2. Rhizoma Curcumae Longae, Semen Myristicae, dry and soft, Actinolitum, Radix Glycyrrhizae, Rhizoma Zingiberis, Fructus cari carvi, Rhizoma Acori Calami, Pericarpium Zanthoxyli and trona are picked totally, be ground into the superfine powder that particle diameter is 1-10 μ m;

The B method:

1. artificial Moschus or Moschus are ground to form fine powder;

3. take by weighing 20% of hybrid medicine total amount that 2. above-mentioned steps obtain, boil 3 times with 15 times of decoctings of medicine gross weight, the each decoction 1 hour, collection, merge extractive liquid, and volatile oil, it is the concentrated solution of 1.35-1.45 that filtration and concentrated extracting solution become relative density, and volatile oil joined in the concentrated solution, concentrated solution a;

Or take by weighing 20% of above-mentioned hybrid medicine total amount, and 40% ethanol extraction that usefulness medicine gross weight is 15 times 3 times extracted 1 hour at every turn, collected extracting solution, filtered, and being condensed into relative density is the concentrated solution a of 1.35-1.45;

4. will remain hybrid medicine and be ground into the superfine powder that particle diameter is 1-10 μ m;

The A method:

1. artificial Moschus or Moschus are ground to form fine powder;

2. Rhizoma Curcumae Longae, Semen Myristicae, dry and soft, Actinolitum, Radix Glycyrrhizae, Rhizoma Zingiberis, Fructus cari carvi, Rhizoma Acori Calami, Pericarpium Zanthoxyli and trona are picked totally, be ground into the superfine powder that particle diameter is 10-40 μ m;

The B method:

1. artificial Moschus or Moschus are ground to form fine powder;

3. take by weighing 50% of hybrid medicine total amount that 2. above-mentioned steps obtain, boil 1 time with 20 times of decoctings of medicine gross weight, the each decoction 1.5 hours, collection, merge extractive liquid, and volatile oil, it is the concentrated solution of 1.15-1.25 that filtration and concentrated extracting solution become relative density, and volatile oil joined in the concentrated solution, concentrated solution a;

Or take by weighing 50% of above-mentioned hybrid medicine total amount, and 50% ethanol extraction that usefulness medicine gross weight is 20 times 1 time extracted 1.5 hours at every turn, collected extracting solution, filtered, and being condensed into relative density is the concentrated solution a of 1.15-1.25;

4. will remain hybrid medicine and be ground into the superfine powder that particle diameter is 10-40 μ m;

The A method:

1. artificial Moschus or Moschus are ground to form fine powder;

2. Rhizoma Curcumae Longae, Semen Myristicae, dry and soft, Actinolitum, Radix Glycyrrhizae, Rhizoma Zingiberis, Fructus cari carvi, Rhizoma Acori Calami, Pericarpium Zanthoxyli and trona are picked totally, be ground into the medicated powder that particle diameter is 40-60 μ m;

3. the artificial Moschus or the Moschus fine powder mix homogeneously that 1. obtain of medicated powder that 2. above-mentioned steps is obtained and step, add buffer agent, cosolvent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention;

The B method:

1. artificial Moschus or Moschus are ground to form fine powder;

3. take by weighing 60% of hybrid medicine total amount that 2. above-mentioned steps obtain, boil 2 times with 10 times of decoctings of medicine gross weight, the each decoction 2.5 hours, collection, merge extractive liquid, and volatile oil, it is the concentrated solution of 1.05-1.15 that filtration and concentrated extracting solution become relative density, and volatile oil joined in the concentrated solution, concentrated solution a;

Or take by weighing 60% of above-mentioned hybrid medicine total amount, and 80% ethanol extraction that usefulness medicine gross weight is 10 times 2 times extracted 20 hours at every turn, collected extracting solution, filtered, and being condensed into relative density is the concentrated solution a of 1.05-1.15;

4. will remain hybrid medicine and be ground into the medicated powder that particle diameter is 40-60 μ m;

5. the medicated powder that 4. artificial Moschus that 1. concentrated solution a that 3. above-mentioned steps is obtained and step obtain or Moschus fine powder, step obtain, mix homogeneously, add buffer agent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention;

Or after the concentrated solution a spray drying that 3. above-mentioned steps is obtained the medicated powder that 4. obtains of the artificial Moschus that 1. obtains of extract dry powder and step or Moschus fine powder, step, mix homogeneously, add buffer agent, cosolvent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

The A method:

1. artificial Moschus or Moschus are ground to form fine powder;

2. Rhizoma Curcumae Longae, Semen Myristicae, dry and soft, Actinolitum, Radix Glycyrrhizae, Rhizoma Zingiberis, Fructus cari carvi, Rhizoma Acori Calami, Pericarpium Zanthoxyli and trona are picked totally, be ground into the medicated powder that particle diameter is 60-90 μ m;

The B method:

1. artificial Moschus or Moschus are ground to form fine powder;

3. take by weighing 90% of hybrid medicine total amount that 2. above-mentioned steps obtain, boil 2 times with 10 times of decoctings of medicine gross weight, the each decoction 2.5 hours, collection, merge extractive liquid, and volatile oil, it is the concentrated solution of 1.15-1.25 that filtration and concentrated extracting solution become relative density, and volatile oil joined in the concentrated solution, concentrated solution a;

Or take by weighing 90% of above-mentioned hybrid medicine total amount, and 90% ethanol extraction that usefulness medicine gross weight is 10 times 1 time extracted 24 hours at every turn, collected extracting solution, filtered, and being condensed into relative density is the concentrated solution a of 1.15-1.25;

4. will remain hybrid medicine and be ground into the medicated powder that particle diameter is 60-90 μ m;

The A method:

1. artificial Moschus or Moschus are ground to form fine powder;

2. Rhizoma Curcumae Longae, Semen Myristicae, dry and soft, Actinolitum, Radix Glycyrrhizae, Rhizoma Zingiberis, Fructus cari carvi, Rhizoma Acori Calami, Pericarpium Zanthoxyli and trona are picked totally, be ground into the medicated powder that particle diameter is 90-150 μ m;

The B method:

1. artificial Moschus or Moschus are ground to form fine powder;

3. take by weighing the mixed material medicine that 2. above-mentioned steps obtains, boil 3 times, decocted 2 hours at every turn with 10 times of weight decoctings, collection, merge extractive liquid, and volatile oil, it is the concentrated solution of 1.05-1.15 that filtration and concentrated extracting solution become relative density, and volatile oil is joined in the concentrated solution, gets concentrated solution a;

Or take by weighing above-mentioned mixed material medicine, and use 60% ethanol extraction 3 times of 10,8,6 times of medicine gross weights respectively, extracted respectively 90,60,30 minutes at every turn, collect extracting solution, filter, being condensed into relative density is the concentrated solution a of 1.05-1.15;

4. artificial Moschus that 1. concentrated solution a that 3. above-mentioned steps is obtained and step obtain or Moschus fine powder mix homogeneously, add buffer agent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention;

Or after the concentrated solution a spray drying that 3. above-mentioned steps is obtained extract dry powder and the step artificial Moschus or the Moschus fine powder that 1. obtain, mix homogeneously, add buffer agent, cosolvent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Nasal formulations of the present invention is compared with prior art the lung-pulse ointment has following characteristics:

1, the present invention adopts the preparation method of part medicinal material extract part medical material ultra micro, has both kept effective ingredient in the medical material effectively, has improved the content of crude drug composition again greatly, has improved bioavailability, makes curative effect better.

2, the adjuvant good moldability selected for use of the present invention, thus the good penetrability of product made, absorb better, onset is faster.

3, nasal formulations of the present invention has convenient drug administration, longer duration, and irritated rate is low, and is easy to use and carry, not advantage such as pollution clothes.

4, the present invention adopts the nasal mucosa medicine administration system, absorbs soon, and onset is rapid, and does not have any stimulation and bad smell.

Following experimental example and embodiment are used to further specify but are not limited to the present invention.

The analgesia effect experiment of experimental example 1 nasal formulations of the present invention

1 reagent, animal and instrument

1.1 reagent

The lung-pulse ointment (XiZang QiZheng Tibetan pharmaceuticals Co., Ltd provides) of conventional dosage forms;

The lung-pulse ointment 1 (preparation method: 1. Rhizoma Curcumae Longae 18g, Semen Myristicae 6g, Radix Et Rhizoma Nardostachyos 12g, Actinolitum 6g, Radix Glycyrrhizae 8g, artificial Moschus 0.08g, Rhizoma Zingiberis 12g, Fructus cari carvi 16g, Rhizoma Acori Calami 8g, Pericarpium Zanthoxyli 6g, trona 9g are made only, pulverize, mix homogeneously, standby; 2. take by weighing 50% of mixed powder gross weight, decoct with water 1 time, collect volatile oil simultaneously, amount of water is 20 times of medical material gross weight, and 80 ℃ of temperature were fried in shallow oil 1.5 hours, collects decocting liquid; Collecting decoction and volatile oil filter, and are condensed into proportion and are 1.0 concentrated solution, and is standby; 3. will remain medicated powder (50%) be ground into the medicated powder of 0.01～200 μ m after, mix with concentrated medicament, 45g octadecanol, 200g water, stir, obtain the mixed liquor of medicinal liquid and water, be warming up to 75 ℃ standby; 4. get the 100g lanoline, gained mixed liquor in adding 3. when being warming up to 75 ℃ stirs, and is to place in the homogenizer under the condition of 0.09MPa to stir 20 minutes fast keeping vacuum pressure, treat that temperature reduces to 30 ℃, add and promptly make ointment after the artificial Moschus stirs.)；

The lung-pulse ointment 2 (preparation method: 1. Rhizoma Curcumae Longae 18g, Semen Myristicae 6g, Radix Et Rhizoma Nardostachyos 12g, Actinolitum 6g, Radix Glycyrrhizae 8g, artificial Moschus 0.08g, Rhizoma Zingiberis 12g, Fructus cari carvi 16g, Rhizoma Acori Calami 8g, Pericarpium Zanthoxyli 6g, trona 9g are made only, pulverize, mix homogeneously, standby; 2. take by weighing 50% of mixed powder gross weight, the alcohol reflux with 50% 1 time extracted 1.5 hours, and alcohol adding amount is 20 times of medical material gross weight, and 50 ℃ of temperature are collected extracting solution; Filter, be condensed into proportion and be 1.0 concentrated solution, standby; 3. will remain medicated powder (50%) be ground into the medicated powder of 0.01～200 μ m after, mix with concentrated medicament, 45g octadecanol, 200g water, stir, obtain the mixed liquor of medicinal liquid and water, be warming up to 75 ℃ standby; 4. get the 100g lanoline, gained mixed liquor in adding 3. when being warming up to 75 ℃ stirs, and is to place in the homogenizer under the condition of 0.09MPa to stir 20 minutes fast keeping vacuum pressure, treat that temperature reduces to 30 ℃, add and promptly make ointment after the artificial Moschus stirs.)；

The lung-pulse ointment 3 (preparation method: 1. Moschus is ground to form fine powder for 0.08 part; 2. with 20 parts in Rhizoma Curcumae Longae, 5 parts of Semen Myristicaes, 10 parts of Radix Et Rhizoma Nardostachyos, 5 parts of Actinolitum, 8 parts in Radix Glycyrrhizae,, 10 parts of 12 parts of Rhizoma Kaempferiaes, 15 parts of Fructus cari carvis, 8 parts of Rhizoma Acori Calamis, 7 parts in Pericarpium Zanthoxyli, trona pick totally, is ground into the superfine powder that particle diameter is 10～40 μ m; , 3. get step superfine powder 2. and place container for 20 parts, add 8 parts liquid paraffin therein, 8 parts glycerol, 9 parts of Tween-80s, 0.2 part of methyl hydroxybenzoate, add water to 100 parts, stir system cream at 75～85 ℃, add Moschus when waiting to be cooled to 35～40 ℃ and stir, make ointment, discharging, room temperature was placed 3～8 hours, and the adding antiseptic is an amount of, and packing promptly.)；

Nasal formulations of the present invention (embodiment 1 is prepared from the description according to the present invention), glacial acetic acid etc.

1.2 instrument

The portable balance of electronics (model: YB1201, Haikang, Shanghai Electronic Instruments Plant); Stopwatch (SW8-2008); Syringe (specification: 1ml) etc.

1.3 animal

Kunming mouse, body weight 20 ± 2g, 4 monthly ages female Mus.

2 methods and result

2.1 method

Get 48 of Kunming mouses, be divided into 6 groups at random, 8 every group, be made as blank group (I), the lung-pulse ointment group (II) of conventional dosage forms, the lung-pulse ointment 1 group of (III), the lung-pulse ointment 2 groups of (IV), the lung-pulse ointment 3 groups of (V), nasal formulations of the present invention (VI) respectively.Except that the blank group, other each groups purify the mouse back hair with barium sulfide before the experiment.II, III, IV, V organize back depilation place respectively and smear administration, dosage is 0.4g/kg (crude drug in whole), nasal formulations group of the present invention (VI) drips medicinal liquid of the present invention (quite crude drug in whole 0.4g/kg) with the syringe nasal cavity, blank group drips the equivalent distilled water with the syringe nasal cavity, administration every day 1 time, successive administration 3 days.Last administration 1h pneumoretroperitoneum is only injected 0.6% acetum 0.2ml/, turns round the body number of times in the 15min behind the record injection acetic acid, calculates the suppression ratio of medicine to writhing response.Pass judgment on medicine analgesic effect: suppression ratio %=(matched group is turned round body average-reagent group and turned round the body average)/matched group is turned round body average * 100%.

2.2 result

Adopt the SPSS11.5 statistical software to carry out date processing, there were significant differences (P＜0.05) for the lung-pulse ointment group (II) of apparent blank group of result and conventional dosage forms, and other each groups all have the outstanding property difference (P＜0.01) of salient pole.The lung-pulse ointment group (II) of prompting conventional dosage forms and the lung-pulse ointment 1 group of (III), the lung-pulse ointment 2 groups of (IV), the lung-pulse ointment 3 groups of (V), nasal formulations groups of the present invention (VI) all can suppress acetic acid actuating thing and turn round body, have analgesic activity.Do not have significant difference between three groups of III, IV, the V, and all have significant difference (P＜0.05) between II, the VI group.The analgesic activity of prompting the lung-pulse ointment 1 group (III), the lung-pulse ointment 2 groups (IV), the lung-pulse ointment 3 groups (V) is better than the lung-pulse ointment group (II) of conventional dosage forms, and the analgesic activity of nasal formulations of the present invention is better than the lung-pulse ointment group (II), the lung-pulse ointment 1 group of (III), the lung-pulse ointment 2 groups of (IV) and 3 groups of the lung-pulse ointment (V) of conventional dosage forms, the results are shown in Table 1.

Table 1 nasal formulations Dichlorodiphenyl Acetate of the present invention causes the inhibition result of mouse writhing reaction

(compare △ P＜0.05, △ △ P＜0.01 with the I group; Compare with the II group ^*P＜0.05, ^*P＜0.01; I and VI group be ★ P＜0.05 relatively, ★ ★ P＜0.01)

Experimental example 2 nasal formulations of the present invention are to the effect experiment of cilium persistent movement time effects

1 reagent, animal and instrument

1.1 reagent

Nasal formulations of the present invention (embodiment 1 is prepared from the description according to the present invention).

1.2 instrument and animal

Bufo siccus 35～45g, operating scissors, microscope, microscope slide, coverslip, stopwatch etc.

2.1 method

Press table 1 grouping, establish 3 groups of 2 groups of 1 group of the lung-pulse ointment group, the lung-pulse ointment, the lung-pulse ointment, the lung-pulse ointment of normal saline group (blank), conventional dosage forms, nasal formulations group of the present invention.Bufo siccus is fixed, use the mosquito forceps tractive, the oral cavity is opened, separate the palate mucosa with operating scissors, get the mucosa of about 3mm * 3mm, clean foreign body with normal saline, mucous membrane surface is tiled on the microscope slide up, drips medicinal liquid by table 1 dosage in mucous membrane surface, and the normal saline group drips the equivalent normal saline, covered gently, and begin to clock, the motion conditions in 40 times of optical microscopes are observed the mucosa cilium down is held in the chromatography cylinder that is added with a small amount of distilled water subsequently, airtight, make steam closely saturated.After this every interval appropriate time takes out specimen, microscopic examination, continuing swing as cilium puts back in the chromatography cylinder, stop swinging until cilium, record begins to stop the used time to fibre swing from administration, with the administration group fibre swing persistent period divided by the matched group time, obtain the relative percentage of cilium persistent movement time, estimate the stimulation of medicine to mucosa.

2.2 result

Adopt SPSS software analysis data, the result shows between 3 groups of normal saline group and conventional dosage forms the lung-pulse ointment group, 1 group of the lung-pulse ointment, 2 groups of the lung-pulse ointment, the lung-pulse ointment all utmost point significant difference (P＜0.01), and there is not significant difference between the nasal formulations group of the present invention, illustrate that the present invention is less to the influence of mucosa cilium persistent movement time, point out nasal formulations of the present invention less, the results are shown in Table 2 the mucosa irritation effect.

Table 2 nasal formulations of the present invention is to the influence of persistent movement time of mucosa cilium

(comparing △ P＜0.05, △ △ P＜0.01) with the normal saline group

Following embodiment all can realize the effect of above-mentioned experimental example

The specific embodiment

Embodiment 1: nasal formulations of the present invention

Crude drug is formed:

Rhizoma Curcumae Longae 36.3g, Semen Myristicae 12.1g, Radix Et Rhizoma Nardostachyos 19.4g, Actinolitum 12.1g, Radix Glycyrrhizae 17.0g, artificial Moschus 0.17g, Rhizoma Zingiberis 24.2g, Fructus cari carvi 31.5g, Rhizoma Acori Calami 17.0g, Pericarpium Zanthoxyli 12.1g, trona 18.2g;

Adjuvant is formed:

Borax sodium carbonate buffer 580ml, glycerol 30g, sodium chloride 30g, sodium sulfite 10g, sodium bicarbonate solution 15ml, sodium benzoate 3.0g;

Method for making:

1. the artificial Moschus is ground to form fine powder;

3. artificial Moschus's fine powder mix homogeneously of 1. obtaining of superfine powder that 2. above-mentioned steps is obtained and step, add Borax sodium carbonate buffer, glycerol, sodium sulfite, sodium chloride, sodium benzoate, stir, adding a small amount of sodium bicarbonate solution accent pH value again is about 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 2: nasal formulations of the present invention

Crude drug is formed:

Rhizoma Curcumae Longae 36.3g, Semen Myristicae 12.1g, Radix Et Rhizoma Nardostachyos 19.4g, Actinolitum 12.1g, Radix Glycyrrhizae 17.0g, Moschus 0.17g, Rhizoma Zingiberis 24.2g, Fructus cari carvi 31.5g, Rhizoma Acori Calami 17.0g, Pericarpium Zanthoxyli 12.1g, trona 18.2g;

Adjuvant is formed:

Phosphate buffer 550ml, propylene glycol 12g, glucose 17.5g, sodium pyrosulfite 10g, disodium phosphate soln 10ml, methyl hydroxybenzoate 2.5g;

Method for making:

1. Moschus is ground to form fine powder;

3. the Moschus fine powder mix homogeneously that 1. obtains of superfine powder that 2. above-mentioned steps is obtained and step, add phosphate buffer, propylene glycol, glucose, sodium pyrosulfite, methyl hydroxybenzoate, stir, adding small amounts of phosphoric acid disodium hydrogen solution accent pH value again is about 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 3: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Borate buffer solution 600ml, ethanol 15g, mannitol 20g, sodium sulfite 18g, sodium hydroxide solution 20ml, sorbic acid 2.5g;

Method for making:

1. the artificial Moschus is ground to form fine powder;

3. artificial Moschus's fine powder mix homogeneously of 1. obtaining of superfine powder that 2. above-mentioned steps is obtained and step, add borate buffer solution, ethanol, mannitol, sodium sulfite, sorbic acid, stir, adding small amounts of sodium hydroxide solution accent pH value again is 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 4: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Acetate buffer 410ml, propylene glycol 20g, sorbitol 15g, disodiumedetate 12g, liquor sodii citratis 15ml, phenethanol 1.5g;

Method for making:

1. Moschus is ground to form fine powder;

3. the Moschus fine powder mix homogeneously that 1. obtains of medicated powder that 2. above-mentioned steps is obtained and step, add acetate buffer, propylene glycol, sorbitol, disodiumedetate, phenethanol, stir, adding small amounts of citric acid sodium solution accent pH value again is about 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 5: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Phosphate buffer 425ml, glycerol 45g, xylitol 28g, sodium thiosulfate 25g, sodium bicarbonate solution 35ml, ethyl hydroxybenzoate 5.0g;

Method for making:

1. Moschus is ground to form fine powder;

3. the Moschus fine powder mix homogeneously that 1. obtains of medicated powder that 2. above-mentioned steps is obtained and step, add phosphate buffer, glycerol, xylitol, sodium thiosulfate, ethyl hydroxybenzoate, stir, adding a small amount of sodium bicarbonate solution accent pH value again is about 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 6: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Acetate buffer 530ml, ethanol 22g, sodium chloride 14g, citric acid 7.5g, sodium hydroxide solution 10ml, propylparaben 2.0g;

Method for making:

1. the artificial Moschus is ground to form fine powder;

3. artificial Moschus's fine powder mix homogeneously of 1. obtaining of medicated powder that 2. above-mentioned steps is obtained and step, add acetate buffer, ethanol, sodium chloride, citric acid, propylparaben, stir, adding small amounts of sodium hydroxide solution accent pH value again is about 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 7: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Phosphate buffer 600ml, sodium chloride 150g, ascorbic acid 60g, sodium bicarbonate solution 50ml, sodium benzoate 9.0g;

Method for making:

1. Moschus is ground to form fine powder;

3. take by weighing 10% of above-mentioned mixed material medicine total amount, boil 4 times, decocted 3 hours at every turn with 5 times of weight decoctings, collection, merge extractive liquid, and volatile oil, it is the concentrated solution of 1.25-1.35 that filtration and concentrated extracting solution become relative density, and volatile oil is joined in the concentrated solution, gets concentrated solution a;

5. the Moschus fine powder that 1. concentrated solution a that 3. above-mentioned steps is obtained and step obtain, the superfine powder that 4. step obtains, mix homogeneously, add phosphate buffer, sodium chloride, ascorbic acid, sodium benzoate, stir, adding a small amount of sodium bicarbonate solution accent pH value again is about 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 8: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Borax sodium carbonate buffer 515ml, glucose 12g, tartaric acid 7g, sodium hydroxide solution 20ml, butoben 1.5g;

Method for making:

1. the artificial Moschus is ground to form fine powder;

3. take by weighing 20% of above-mentioned mixed material medicine total amount, boil 3 times, decocted 1 hour at every turn with 15 times of weight decoctings, collection, merge extractive liquid, and volatile oil, it is the concentrated solution of 1.35-1.45 that filtration and concentrated extracting solution become relative density, and volatile oil is joined in the concentrated solution, gets concentrated solution a;

5. artificial Moschus's fine powder that 1. concentrated solution a that 3. above-mentioned steps is obtained and step obtain, the superfine powder that 4. step obtains, mix homogeneously, add Borax sodium carbonate buffer, glucose, tartaric acid, butoben, stir, adding small amounts of sodium hydroxide solution accent pH value again is about 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 9: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Acetate buffer 2850ml, mannitol 550g, ethylenediaminetetraacetic acid 350g, disodium phosphate soln 150ml, sorbic acid 20g;

Method for making:

1. the artificial Moschus is ground to form fine powder;

3. take by weighing 50% of above-mentioned mixed material medicine total amount, boil 1 time, decocted 1.5 hours at every turn with 20 times of weight decoctings, collection, merge extractive liquid, and volatile oil, it is the concentrated solution of 1.15-1.25 that filtration and concentrated extracting solution become relative density, and volatile oil is joined in the concentrated solution, gets concentrated solution a;

5. artificial Moschus's fine powder that 1. concentrated solution a that 3. above-mentioned steps is obtained and step obtain, the superfine powder that 4. step obtains, mix homogeneously, add acetate buffer, mannitol, ethylenediaminetetraacetic acid, sorbic acid, stir, adding small amounts of phosphoric acid disodium hydrogen solution accent pH value again is about 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 10: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Borate buffer solution 620ml, xylitol 150g, sodium sulfite 85g, liquor sodii citratis 50ml, phenethanol 5.0g;

1. the artificial Moschus is ground to form fine powder;

3. take by weighing 60% of above-mentioned mixed material medicine total amount, boil 2 times, decocted 2.5 hours at every turn with 10 times of weight decoctings, collection, merge extractive liquid, and volatile oil, it is the concentrated solution of 1.05-1.15 that filtration and concentrated extracting solution become relative density, and volatile oil is joined in the concentrated solution, gets concentrated solution a;

5. artificial Moschus's fine powder that 1. concentrated solution a that 3. above-mentioned steps is obtained and step obtain, the medicated powder that 4. step obtains, mix homogeneously, add borate buffer solution, xylitol, sodium sulfite, phenethanol, stir, adding small amounts of citric acid sodium solution accent pH value again is about 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 11: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Phosphate buffer 580ml, sodium chloride 180g, sodium sulfite 115g, sodium bicarbonate solution 60ml, methyl hydroxybenzoate 4.5g;

1. the artificial Moschus is ground to form fine powder;

3. take by weighing 90% of above-mentioned mixed material medicine total amount, boil 2 times, decocted 2.5 hours at every turn with 10 times of weight decoctings, collection, merge extractive liquid, and volatile oil, it is the concentrated solution of 1.15-1.25 that filtration and concentrated extracting solution become relative density, and volatile oil is joined in the concentrated solution, gets concentrated solution a;

5. artificial Moschus's fine powder that 1. concentrated solution a that 3. above-mentioned steps is obtained and step obtain, the medicated powder that 4. step obtains, mix homogeneously, add phosphate buffer, sodium chloride, sodium sulfite, methyl hydroxybenzoate, stir, adding a small amount of sodium bicarbonate solution accent pH value again is about 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 12: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Borax sodium carbonate buffer 650ml, mannitol 150g, disodiumedetate 100g, disodium phosphate soln 50ml, propylparaben 5.0g;

1. the artificial Moschus is ground to form fine powder;

3. take by weighing above-mentioned mixed material medicine, boil 3 times, decocted 2 hours at every turn with 10 times of weight decoctings, collection, merge extractive liquid, and volatile oil, it is the concentrated solution of 1.05-1.15 that filtration and concentrated extracting solution become relative density, and volatile oil is joined in the concentrated solution, gets concentrated solution a;

4. artificial Moschus's fine powder that 1. concentrated solution a that 3. above-mentioned steps is obtained and step obtain, mix homogeneously, add Borax sodium carbonate buffer, mannitol, disodiumedetate, propylparaben, stir, adding small amounts of phosphoric acid disodium hydrogen solution accent pH value again is about 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 13: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Phosphate buffer 450ml, glycerol 160g, glucose 120g, sodium pyrosulfite 65g, sodium hydroxide solution 50ml, methyl hydroxybenzoate 2.5g;

Method for making:

1. Moschus is ground to form fine powder;

5. the concentrated solution a spray drying that 3. above-mentioned steps is obtained, after drying the Moschus fine powder that 1. obtains of extract dry powder and step, the superfine powder that 4. step obtains, mix homogeneously, add phosphate buffer, glycerol, glucose, sodium pyrosulfite, methyl hydroxybenzoate, stir, adding small amounts of sodium hydroxide solution accent pH value again is about 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 14: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Acetate buffer 1750ml, propylene glycol 1050g, sorbitol 580g, sodium thiosulfate 350g, sodium bicarbonate solution 100ml, sodium benzoate 8.5g;

Method for making:

1. the artificial Moschus is ground to form fine powder;

5. the concentrated solution a spray drying that 3. above-mentioned steps is obtained, after drying artificial Moschus's fine powder of 1. obtaining of extract dry powder and step, the superfine powder that 4. step obtains, mix homogeneously, add acetate buffer, propylene glycol, sorbitol, sodium thiosulfate, sodium benzoate, stir, adding a small amount of sodium bicarbonate solution accent pH value again is about 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 15: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Phosphate buffer 400ml, ethanol 200g, glucose 150g, ethylenediaminetetraacetic acid 85g, liquor sodii citratis 45ml, propylparaben 7.5g;

Method for making:

1. Moschus is ground to form fine powder;

5. the concentrated solution a spray drying that 3. above-mentioned steps is obtained, after drying the Moschus fine powder that 1. obtains of extract dry powder and step, the superfine powder that 4. step obtains, mix homogeneously, add phosphate buffer, ethanol, glucose, ethylenediaminetetraacetic acid, propylparaben, stir, adding small amounts of citric acid sodium solution accent pH value again is about 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 16: nasal formulations of the present invention

Crude drug is formed:

Rhizoma Curcumae Longae 36.3g, Semen Myristicae 12.1g, Radix Et Rhizoma Nardostachyos, 19.4g, Actinolitum 12.1g, Radix Glycyrrhizae 17.0g, artificial Moschus 0.17g, Rhizoma Zingiberis 24.2g, Fructus cari carvi 31.5g, Rhizoma Acori Calami 17.0g, Pericarpium Zanthoxyli 12.1g, trona 18.2g;

Adjuvant is formed:

Borax sodium carbonate buffer 540ml, glycerol 180g, sodium chloride 90g, ascorbic acid 75g, disodium phosphate soln 70ml, phenethanol 4.5g;

1. the artificial Moschus is ground to form fine powder;

5. the concentrated solution a spray drying that 3. above-mentioned steps is obtained, after drying artificial Moschus's fine powder of 1. obtaining of extract dry powder and step, the medicated powder that 4. step obtains, mix homogeneously, add Borax sodium carbonate buffer, glycerol, sodium chloride, ascorbic acid, phenethanol, stir, adding small amounts of phosphoric acid disodium hydrogen solution accent pH value again is about 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 17: nasal formulations of the present invention

Crude drug is formed:

Rhizoma Curcumae Longae 36.3g, Semen Myristicae 12.1g, Radix Et Rhizoma Nardostachyos, 19.4g, Actinolitum 12.1g, Radix Glycyrrhizae 17.0g, Moschus 0.17g, Rhizoma Zingiberis 24.2g, Fructus cari carvi 31.5g, Rhizoma Acori Calami 17.0g, Pericarpium Zanthoxyli 12.1g, trona 18.2g;

Adjuvant is formed:

Acetate buffer 420ml, propylene glycol 195g, xylitol 160g, sodium sulfite 120g, sodium bicarbonate solution 80ml, methyl hydroxybenzoate 2.5g;

1. Moschus is ground to form fine powder;

5. the concentrated solution a spray drying that 3. above-mentioned steps is obtained, after drying the Moschus fine powder that 1. obtains of extract dry powder and step, the medicated powder that 4. step obtains, mix homogeneously, add acetate buffer, propylene glycol, xylitol, sodium sulfite, methyl hydroxybenzoate, stir, adding a small amount of sodium bicarbonate solution accent pH value again is about 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 18: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Phosphate buffer 355ml, glycerol 85g, glucose 18g, tartaric acid 12g, sodium hydroxide 30ml, sodium benzoate 2.5g;

1. the artificial Moschus is ground to form fine powder;

4. the concentrated solution a spray drying that 3. above-mentioned steps is obtained, get artificial Moschus's fine powder that 1. extract dry powder and step obtain after drying, mix homogeneously, add phosphate buffer, glycerol, glucose, tartaric acid, sodium benzoate, stir, adding small amounts of sodium hydroxide solution accent pH value again is about 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations of the present invention.

Embodiment 19: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Method for making:

1. Moschus is ground to form fine powder;

3. take by weighing 10% of above-mentioned mixed material medicine total amount, with 30% ethanol extraction of 5 times of weight 4 times, extracted 3 hours at every turn, collect extracting solution, filter, being condensed into relative density is the concentrated solution a of 1.25-1.35;

Embodiment 20: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Borax sodium carbonate buffer 415ml, glucose 25g, tartaric acid 18g, sodium hydroxide solution 20ml, butoben 1.5g;

Method for making:

1. the artificial Moschus is ground to form fine powder;

3. take by weighing 20% of above-mentioned mixed material medicine total amount, with 40% ethanol extraction of 15 times of weight 3 times, extracted 1 hour at every turn, collect extracting solution, filter, being condensed into relative density is the concentrated solution a of 1.35-1.45;

Embodiment 21: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Method for making:

1. the artificial Moschus is ground to form fine powder;

3. take by weighing 50% of above-mentioned mixed material medicine total amount, with 50% ethanol extraction of 20 times of weight 1 time, extracted 1.5 hours at every turn, collect extracting solution, filter, being condensed into relative density is the concentrated solution a of 1.15-1.25;

Embodiment 22: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

1. the artificial Moschus is ground to form fine powder;

3. take by weighing 60% of above-mentioned mixed material medicine total amount, with 80% ethanol extraction of 10 times of weight 2 times, extracted 20 hours at every turn, collect extracting solution, filter, being condensed into relative density is the concentrated solution a of 1.05-1.15;

Embodiment 23: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

1. the artificial Moschus is ground to form fine powder;

3. take by weighing 90% of above-mentioned mixed material medicine total amount, with 90% ethanol extraction of 10 times of weight 1 time, extracted 24 hours at every turn, collect extracting solution, filter, being condensed into relative density is the concentrated solution a of 1.15-1.25;

Embodiment 24: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

1. the artificial Moschus is ground to form fine powder;

3. take by weighing above-mentioned mixed material medicine, use 60% ethanol extraction 3 times of 10,8,6 times of medicine gross weights respectively, extracted respectively 90,60,30 minutes at every turn, collect extracting solution, filter, being condensed into relative density is the concentrated solution a of 1.05-1.15;

Embodiment 25: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Method for making:

1. Moschus is ground to form fine powder;

Embodiment 26: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Method for making:

1. the artificial Moschus is ground to form fine powder;

Embodiment 27: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Phosphate buffer 400ml, ethanol 200g, glucose 150g, ethylenediaminetetraacetic acid 85g, liquor sodii citratis 45ml, propylparaben 4.5g;

Method for making:

1. Moschus is ground to form fine powder;

Embodiment 28: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

1. the artificial Moschus is ground to form fine powder;

Embodiment 29: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

1. Moschus is ground to form fine powder;

Embodiment 30: nasal formulations of the present invention

Crude drug is formed:

Adjuvant is formed:

Phosphate buffer 600ml, glycerol 85g, glucose 30g, tartaric acid 28g, sodium hydroxide 30ml, sodium benzoate 2.5g;

1. the artificial Moschus is ground to form fine powder;

Claims

1. nasal formulations for the treatment of aortic arch syndrome, its crude drug consists of: Rhizoma Curcumae Longae 30-40 weight portion, Semen Myristicae 10-15 weight portion, Radix Et Rhizoma Nardostachyos 15-25 weight portion, Actinolitum 10-15 weight portion, Radix Glycyrrhizae 15-20 weight portion, artificial Moschus or Moschus 0.15-0.2 weight portion, Rhizoma Zingiberis 20-28 weight portion, Fructus cari carvi 28-35 weight portion, Rhizoma Acori Calami 15-20 weight portion, Pericarpium Zanthoxyli 10-15 weight portion, trona 15-20 weight portion; The adjuvant that it is characterized in that this nasal formulations consists of:

2. nasal formulations as claimed in claim 1 is characterized in that the adjuvant of this nasal formulations consists of:

3. nasal formulations as claimed in claim 1 is characterized in that the adjuvant of this nasal formulations consists of:

4. nasal formulations as claimed in claim 1 is characterized in that the adjuvant of this nasal formulations consists of:

5. nasal formulations as claimed in claim 1 is characterized in that the adjuvant of this nasal formulations consists of:

6. nasal formulations as claimed in claim 1 is characterized in that the adjuvant of this nasal formulations consists of:

Or acetate buffer 410 parts by volume, propylene glycol 20 weight portions, sorbitol 15 weight portions, disodiumedetate 12 weight portions, liquor sodii citratis 15 parts by volume, phenethanol 1.5 weight portions;

7. as the arbitrary described nasal formulations of claim 1-6, it is characterized in that the crude drug of this nasal formulations consists of:

8. as the preparation method of the arbitrary described nasal formulations of claim 2-7, it is characterized in that this method comprises a kind of in following A and the B method:

The A method:

1. artificial Moschus or Moschus are ground to form fine powder;

3. the artificial Moschus or the Moschus fine powder mix homogeneously that 1. obtain of medicated powder that 2. above-mentioned steps is obtained and step, add buffer agent, cosolvent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.0-7.0, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations;

The B method:

1. artificial Moschus or Moschus are ground to form fine powder;

5. the medicated powder that 4. artificial Moschus that 1. concentrated solution a that 3. above-mentioned steps is obtained and step obtain or Moschus fine powder, step obtain, mix homogeneously, add buffer agent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.0-7.0, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations;

Or after the concentrated solution a spray drying that 3. above-mentioned steps is obtained the medicated powder that 4. obtains of the artificial Moschus that 1. obtains of extract dry powder and step or Moschus fine powder, step, mix homogeneously, add buffer agent, cosolvent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.0-7.0, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations.

9. the preparation method of nasal formulations as claimed in claim 8 is characterized in that this method comprises a kind of in following A and the B method:

The A method:

1. artificial Moschus or Moschus are ground to form fine powder;

3. the artificial Moschus or the Moschus fine powder mix homogeneously that 1. obtain of superfine powder that 2. above-mentioned steps is obtained and step, add buffer agent, cosolvent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations;

The B method:

1. artificial Moschus or Moschus are ground to form fine powder;

5. the superfine powder that 4. artificial Moschus that 1. concentrated solution a that 3. above-mentioned steps is obtained and step obtain or Moschus fine powder, step obtain, mix homogeneously, add buffer agent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations;

Or after the concentrated solution a spray drying that 3. above-mentioned steps is obtained the superfine powder that 4. obtains of the artificial Moschus that 1. obtains of extract dry powder and step or Moschus fine powder, step, mix homogeneously, add buffer agent, cosolvent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations.

10. the preparation method of nasal formulations as claimed in claim 8 is characterized in that this method comprises a kind of in following A and the B method:

The A method:

1. artificial Moschus or Moschus are ground to form fine powder;

The B method:

1. artificial Moschus or Moschus are ground to form fine powder;

11. the preparation method of nasal formulations as claimed in claim 8 is characterized in that this method comprises a kind of in following A and the B method:

The A method:

1. artificial Moschus or Moschus are ground to form fine powder;

The B method:

1. artificial Moschus or Moschus are ground to form fine powder;

12. the preparation method of nasal formulations as claimed in claim 8 is characterized in that this method comprises a kind of in following A and the B method:

The A method:

1. artificial Moschus or Moschus are ground to form fine powder;

3. the artificial Moschus or the Moschus fine powder mix homogeneously that 1. obtain of medicated powder that 2. above-mentioned steps is obtained and step, add buffer agent, cosolvent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations;

The B method:

1. artificial Moschus or Moschus are ground to form fine powder;

5. the medicated powder that 4. artificial Moschus that 1. concentrated solution a that 3. above-mentioned steps is obtained and step obtain or Moschus fine powder, step obtain, mix homogeneously, add buffer agent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations;

Or after the concentrated solution a spray drying that 3. above-mentioned steps is obtained the medicated powder that 4. obtains of the artificial Moschus that 1. obtains of extract dry powder and step or Moschus fine powder, step, mix homogeneously, add buffer agent, cosolvent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations.

13. the preparation method of nasal formulations as claimed in claim 8 is characterized in that this method comprises a kind of in following A and the B method:

The A method:

1. artificial Moschus or Moschus are ground to form fine powder;

The B method:

1. artificial Moschus or Moschus are ground to form fine powder;

14. the preparation method of nasal formulations as claimed in claim 8 is characterized in that this method comprises a kind of in following A and the B method:

The A method:

1. artificial Moschus or Moschus are ground to form fine powder;

The B method:

1. artificial Moschus or Moschus are ground to form fine powder;

4. artificial Moschus that 1. concentrated solution a that 3. above-mentioned steps is obtained and step obtain or Moschus fine powder mix homogeneously, add buffer agent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filter, autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations;

Or after the concentrated solution a spray drying that 3. above-mentioned steps is obtained extract dry powder and the step artificial Moschus or the Moschus fine powder that 1. obtain, mix homogeneously, add buffer agent, cosolvent, isotonic agent, stabilizing agent, antibacterial, stir, adding PH regulator accent pH value again is 6.5, filters autoclaving, gained liquid is bottled sealing under aseptic condition, promptly gets nasal formulations.

15. have application in the medicine of analgesic activity in preparation as the arbitrary described nasal formulations of claim 1-6.

16. nasal formulations as claimed in claim 7 has application in the medicine of analgesic activity in preparation.